- Home
- KTF vs HUMAW Comparison
KTF vs HUMAW Comparison
Compare KTF & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KTF | HUMAW |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KTF | HUMAW |
|---|---|---|
| Price | $9.14 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 103.3K | 14.2K |
| Earning Date | 01-01-0001 | 03-21-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.40 | $1.18 |
| 52 Week High | $9.12 | $1.34 |
Technical Indicators
Market Signals| Indicator | KTF | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 44.95 |
| Support Level | $9.09 | $0.11 |
| Resistance Level | $9.21 | $0.15 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 25.00 | 91.78 |
Price Performance
Historical ComparisonAbout KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.